Lynk’s zemprocitinib commercial partner, Simcere, will now continue the JAK inhibitor’s development across China in RA.

Rilzabrutinib (Wayrilz; Sanofi), a BTK inhibitor, targets immune-mediated platelet destruction in immune thrombocytopenia (ITP) and has demonstrated a favorable safety profile.

BioAge’s NLRP3 inhibitor has shown potential to reduce high-sensitivity C-reactive protein (hsCRP), a key marker of ...

ETX-19477 is a potent, selective inhibitor of poly (ADP-ribose) glycohydrolase (PARG), an enzyme that plays a role in the DNA ...

Switching to a second TNF inhibitor in inflammatory bowel disease may raise the risk for immune-mediated inflammatory ...

Exposure to TNF inhibitors during pregnancy and postpartum was not associated with a significantly increased risk for serious infection.

The benefit of PARP inhibitors varied significantly based on the tumor's molecular profile, particularly its homologous recombination repair capability. While patients with deficiencies in this ...

This case describes a woman in her mid-40s with recurrent colorectal cancer who developed severe dermatologic toxicity during ...

Immune checkpoint molecules play a crucial role in keeping the immune system in balance and preventing an attack on the ...

CDK 4/6 inhibitors (CDK4/6i) remain part of the standard first-line treatment for patients with hormone receptor–positive metastatic breast cancer, offering demonstrable improvements in both ...